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Introduction {#sec1}
============

Obesity is a major contributor to numerous metabolic diseases including type 2 diabetes, hypertension, and atherosclerosis. Adipose tissue plays an essential role in regulating the whole-body energy balance. White adipose tissue (WAT) stores excess energy as lipids, whereas brown adipose tissue (BAT) expends energy as heat. The thermogenic properties of BAT are dependent on high oxidative capacity and mitochondrial density and high levels of uncoupling protein 1 (UCP1). Classical brown adipocytes are mainly located around interscapular BAT, whereas beige adipocytes, inducible brown-fat-like cells, sporadically reside in subcutaneous WAT depots ([@bib1]). The emergence of beige adipocytes in WAT is induced by environmental stimuli, including cold exposure, exercise, long-term peroxisome proliferator-activated receptor γ (PPARγ) activation, and β-adrenergic receptor stimulation ([@bib14]). The browning of WAT can prevent diet-induced obesity and improve metabolism ([@bib18]). Notably, recent studies also suggest that these beige adipocytes can significantly contribute to the energy balance in humans ([@bib43]).

Obesity-associated macrophage infiltration in adipose tissues is coupled with the recruitment of proinflammatory M1 macrophages, leading to increased expression of proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) ([@bib31]). These proinflammatory cytokines induce an inflammatory phenotype in adipocytes and prevent adipogenesis of 3T3-L1 cells ([@bib12]). Elevated circulating lipopolysaccharide (LPS) levels in obesity also trigger inflammation in macrophages and preadipocytes of adipose tissues, and LPS treatment inhibits differentiation of adipocyte precursors *in vitro* ([@bib52]). In addition to LPS, interferon-α (IFN-α), a key stimulator of the innate immune response, inhibits adipogenesis of 3T3-L1 cells ([@bib24]). Thus, accumulating evidence indicates that activation of innate immune responses negatively regulates adipocyte differentiation. However, the molecular players that repress innate immune responses in adipocytes remain elusive.

Activating transcription factor 7 (ATF7) belongs to the vertebrate ATF2 subfamily of transcription factors, which has three members: ATF2 (originally named CRE-BP1) ([@bib28], [@bib13]), CRE-BPa ([@bib33]), and ATF7 (originally named ATFa) ([@bib10]). ATF2 proteins reportedly contribute to the regulation of adipocyte differentiation and function. *Atf2*^*+/−*^*Cre-bpa*^*+/−*^ double-heterozygous mice exhibit reduced WAT mass, and bone morphogenetic protein 2 can induce the p38-dependent phosphorylation of ATF2, which binds to the promoter region of *Pparγ2* to stimulate adipocyte differentiation ([@bib27]). The p38-dependent activation of ATF2 is also required for the induction of thermogenic genes, including *Ucp1* ([@bib4]), *Pgc1α* ([@bib2], [@bib50]), and *Zfp516* ([@bib8]), in BAT in response to various stimuli. Although ATF7 shares a relatively high amino acid sequence identity with ATF2, it represses rather than activating, gene expression in the absence of stress ([@bib41]). ATF7 recruits histone methyltransferases to silence the transcription of target genes. Histone H3K9 trimethyltransferase ESET/SETDB1 is recruited by ATF7 to promote the formation of heterochromatin-like structure on the regulatory region of the *Htr5b* gene, which encodes serotonin receptor 5b, in the dorsal raphe nuclei of the brain ([@bib29]). Social isolation stress induces the phosphorylation of ATF7 via p38 and leads to the release of ATF7 and ESET/SETDB1 from target genes, resulting in transcriptional activation. ATF7 represses a group of innate immunity-related genes in macrophages by associating with H3K9 dimethyltransferase G9a. Pathogen-infection-induced phosphorylation of ATF7 stimulates the release of ATF7-G9a from target genes, accompanied by a decrease in repressive histone H3K9me2 levels, leading to elevated gene expression ([@bib51]). In mouse embryonic fibroblast cells, ATF7 regulates H3K9me3 levels on pericentromeric heterochromatin and telomeres by interacting with Suv39h1 ([@bib30]).

Our previous study found that deletion of *Atf7* reduced adipose tissue mass and increased energy expenditure in mice fed a high-fat diet ([@bib26]), implying that ATF7 may participate in the regulation of energy balance. In the present work, we have more precisely analyzed the role of ATF7 in adipocyte differentiation and showed that ATF7 facilitates adipogenesis by repressing innate immune responses, whereas it suppresses beige adipocyte biogenesis via dimethylation of H3K9 on thermogenic gene enhancers. Thus ATF7 has a dual role for the regulation of white adipocyte differentiation and beige fat biogenesis in inguinal white adipose tissue (iWAT).

Results {#sec2}
=======

ATF7 Deficiency Impairs Adipocyte Differentiation {#sec2.1}
-------------------------------------------------

*Atf7*-deficient (*Atf7*^*−/−*^) mice exhibited reduced adipose tissue mass, suggesting that ATF7 may contribute to adipocyte differentiation ([@bib26]). To investigate the function of ATF7 in the regulation of adipocytes, we examined whether ATF7 was expressed in fat tissues. ATF7 was detected in BAT, iWAT, and epididymal WAT ([Figure 1](#fig1){ref-type="fig"}A). The stroma-vascular fraction (SVF) of adipose tissues provides a rich reservoir of adipocyte precursors. We measured the expression levels of *Atf7*, *Wnt10b*, and *Prdm16* genes in isolated mature adipocytes and the SVF from BAT and iWAT. *Wnt10b* expression decreases during adipocyte differentiation ([@bib5]), and *Prdm16* is mainly expressed in mature adipocytes ([@bib39]). In line with previous reports, we also observed that *Wnt10b* was mainly expressed in the SVF, whereas *Prdm16* exhibited higher expression levels in adipocytes than in the SVF ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). However, there was no difference in *Atf7* gene expression in adipocytes from BAT and iWAT. ATF7 was also expressed at comparable levels in the SVF and mature adipocytes ([Figure 1](#fig1){ref-type="fig"}B). To explore the expression of *Atf7* during adipocyte differentiation, we used inguinal primary preadipocytes and measured gene expression by quantitative PCR (qPCR). The results indicated that *Atf7* expression was reduced by 40% (day 2) after cells were cultured in induction medium, and expression then increased to day 0 levels, whereas expression of the adipogenesis marker *Fabp4* gradually increased during adipocyte differentiation ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Loss of ATF7 Impairs Adipogenesis(A) ATF7 protein expression levels in BAT, iWAT, and epididymal WAT measured by immunoblotting.(B) *Atf7* mRNA expression levels in mature adipocytes and stromal vascular cells isolated from BAT and iWAT (n = 3, three biological replicates). Data are presented as mean ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests.(C) *Atf7* (left) and *Fabp4* (right) gene expression during the differentiation time course of primary iWAT preadipocytes (n = 3, three biological replicates).(D) Oil red O staining of wild-type (WT) and *Atf7*^−/−^ primary iWAT preadipocytes at 7 days after induction of differentiation in the absence of rosiglitazone (Rosi).(E) Expression of the common adipogenic genes *Pparγ*, *C/ebpα*, and *C/ebpβ*, detected by real-time PCR during the differentiation time course of WT and *Atf7*^*−/−*^ primary iWAT preadipocytes (n = 3, three biological replicates).(F) Oil red O staining of WT and *Atf7*^*−/−*^ primary iWAT preadipocytes at 7 days after induction of differentiation in the presence of Rosi.(G) *Fabp4* gene expression levels in differentiated WT and *Atf7*^*−/−*^ primary iWAT preadipocytes in the presence or absence of Rosi.Data are presented as means ± SD. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak multiple comparison tests. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 versus WT (without Rosi treatment). See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To determine the function of ATF7 in adipocyte differentiation, we used primary inguinal preadipocytes isolated from wild-type (WT) and *Atf7*^*−/−*^ mice to examine whether loss of ATF7 affects adipogenesis. ATF7 ablation reduced the number of oil red O-stained mature adipocytes ([Figure 1](#fig1){ref-type="fig"}D), and the expression level of adipogenic markers *Pparγ*, *C/ebpα*, and *Fabp4* ([Figures 1](#fig1){ref-type="fig"}E and 1G). By contrast, *C/ebpβ* expression levels were not affected by ATF7 deficiency ([Figure 1](#fig1){ref-type="fig"}E). When cells were induced to undergo adipocyte differentiation in the presence of the PPARγ agonist rosiglitazone (Rosi), which promotes adipogenesis and activates brown-selective genes ([@bib38]), *Atf7* expression exhibited similar changes to those observed in the absence of Rosi, indicating that this agent did not affect *Atf7* expression ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Notably, the presence of Rosi rescued ATF7-deficiency-induced impairment of adipogenesis. Oil red O staining revealed no difference in lipid accumulation between WT and *Atf7*^*−/−*^ cells cultured with Rosi ([Figure 1](#fig1){ref-type="fig"}F). Rosi dramatically up-regulated *Fabp4* expression in both WT and ATF7 knockout (KO) cells, and importantly, *Fabp4* expression in ATF7 KO cells was comparable to that in WT cells in the presence of Rosi ([Figure 1](#fig1){ref-type="fig"}G). Compared with WT cells, the common adipogenic markers *Pparγ*, *C/ebpα*, and *C/ebpβ* also exhibited similar expression levels in *Atf7*^*−/−*^ cells when treated with Rosi ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These findings indicate that ATF7 negatively regulates adipogenesis, directly or indirectly, by repressing *Pparγ* expression.

ATF7 Represses Innate Immune-Related Genes in Adipocytes {#sec2.2}
--------------------------------------------------------

To investigate the mechanism by which ATF7 suppresses adipogenesis, we performed RNA sequencing (RNA-seq) on adipocytes (D7) derived from inguinal preadipocytes in the presence and absence of Rosi. In the absence of Rosi, 673 genes were up-regulated and 237 genes were down-regulated by the loss of ATF7, and Gene Ontology analysis revealed that up-regulated genes were related to immune responses ([Figure 2](#fig2){ref-type="fig"}A). The most enriched pathways associated with these up-regulated genes included innate immune responses, defense responses to viruses, and cellular responses to IFN-β, whereas the down-regulated genes were mainly related to lipid metabolism and storage ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We also identified 200 genes that were up-regulated and 174 genes that were down-regulated in *Atf7*^*−/−*^ cells compared with WT cells in the presence of Rosi, and down-regulated genes were related to positive regulation of angiogenesis, negative regulation of insulin secretion, and cellular response to IL-1 and TNF-α ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Interestingly, pathway analysis for up-regulated genes gave similar results to those obtained from adipocytes cultured without Rosi ([Figure 2](#fig2){ref-type="fig"}B). These up-regulated genes were also mainly associated with immune response pathways, implying that ATF7 may inhibit immune-related gene expression in adipocytes.Figure 2ATF7 Represses Innate Immune Gene Expression in Adipocytes(A and B) Gene Ontology (GO) pathways (Biological Process category) enriched in up-regulated genes in differentiated *Atf7*^*−/−*^ primary iWAT preadipocytes compared with WT controls in the absence (A) or presence (B) of rosiglitazone (Rosi).(C) The interferon-stimulated response element (ISRE)-binding motif is the most enriched DNA motif within the promoters of up-regulated genes induced by loss of ATF7 in differentiated adipocytes.(D) Venn diagram showing the number of overlapping up-regulated genes in *Atf7*^*−/−*^ cells in the presence and absence of Rosi.(E) Heatmap depicting the expression levels of overlapping up-regulated genes in WT and *Atf7*^*−/−*^ cells (n = 2, two biological replicates).(F) Gene expression levels of IFN-stimulated genes (ISGs) in WT and *Atf7*^*−/−*^ primary preadipocytes and differentiated adipocytes at day 7 (D7, n = 3, three biological replicates).Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*p \< 0.05, \*\*p \< 0.01. See also [Figures S3--S5](#mmc1){ref-type="supplementary-material"}.

To clarify the factors potentially modulating these up-regulated genes in *Atf7*^*−/−*^ adipocytes, we performed motif analysis of promoter regions and found that interferon-stimulated response element (ISRE) was the most enriched motif in genes up-regulated in *Atf7*^*−/−*^ cells in both the presence and absence of Rosi. Without Rosi, 6.53% of the 673 gene promotors contain an ISRE, and in the presence of Rosi, this ratio increases to 22.22% ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, 57 genes overlap between the two up-regulated gene sets, including many interferon-stimulated genes (ISGs) such as *Irf7*, *Ifit1*, *Ifit3*, *Rsad2*, and *Oasl2* ([Figures 2](#fig2){ref-type="fig"}D and 2E). In accordance with the RNA-seq data, the results of qPCR demonstrated that ISGs were more highly expressed in *Atf7*^*−/−*^ adipocytes (D7), and they were also increased in *Atf7*^*−/−*^ preadipocytes compared with WT controls ([Figure 2](#fig2){ref-type="fig"}F). To further validate the role of ATF7 in the regulation of ISG expression, we overexpressed ATF7 in the C3H10T1/2 murine mesenchymal stem cell line ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Expression of ISGs was stimulated by treatment with LPS (0.5 μg/mL) for 12 h. However, overexpression of ATF7 significantly repressed ISG expression in the absence and presence of LPS ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Taken together, these results suggest that ATF7 suppresses the induction of ISGs, and loss of ATF7 stimulates ISG expression during adipocyte differentiation.

In contrast to *in vitro* data, the results of qPCR and immunofluorescence staining demonstrated that loss of ATF7 did not affect the inflammation level of iWAT ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Interestingly, we found that loss of ATF7 led to a dramatic reduction in the *Retn* gene expression in adipocytes ([Figure S5](#mmc1){ref-type="supplementary-material"}C). This finding was consistent with the lower circulating resistin observed in the *Atf7*^*−/−*^ mice ([@bib26]). Given the pro-inflammatory properties of resistin in adipose tissue ([@bib35]), the reduction of resistin may counter the adipose tissue inflammation induced by the activation of innate immune response in *Atf7*^*−/−*^ adipocytes. These results suggest that ISGs are up-regulated in *Atf7*^*−/−*^ adipocytes, but it does not cause the inflammation at the tissue level because of negative feedback regulation by resistin.

Activation of ISGs Impairs Adipogenesis {#sec2.3}
---------------------------------------

To examine the effect of the induction of ISGs on adipogenesis, we treated preadipocytes with LPS (0.5 μg/mL) for 24 h and found that LPS treatment dramatically stimulated the expression of ISGs ([Figure S6](#mmc1){ref-type="supplementary-material"}A). By contrast, *Pparγ* expression levels in LPS-treated cells were reduced by approximately half compared with those in phosphate-buffered saline (PBS)-treated control cells ([Figure S6](#mmc1){ref-type="supplementary-material"}B), implying that LPS treatment may impair adipogenesis by repressing *Pparγ* expression. A previous study demonstrated that LPS treatment for 24 h before the induction of adipocyte differentiation results in the profound impairment of adipogenesis ([@bib52]). In line with these previous observations, we also found that adipocyte differentiation was severely blunted by LPS exposure for 24 h before addition of induction medium. In the absence of Rosi, LPS treatment led to decreased lipid accumulation and lower expression levels of adipogenic markers ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). Interestingly, the presence of Rosi during differentiation clearly rescued the impairment of adipogenesis induced by LPS treatment. The results of oil red O staining demonstrated that Rosi mitigates the effect of LPS treatment on lipid accumulation ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Moreover, there was no difference in expression levels of Pparγ between LPS- and PBS-treated cells in the presence of Rosi, although *Fabp4* and *C/ebpα* expression remained slightly reduced following LPS treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}D).

IFN-α can stimulate the expression of ISGs and inhibit adipogenesis in 3T3-L1 cells ([@bib24]). However, the inhibitory effect of IFN-α on adipogenesis in brown adipocyte precursors was not observed ([@bib21]). To examine the effect of IFN-α on adipogenesis in iWAT preadipocytes, we measured the expression of ISGs in preadipocytes following exposure to IFN-α (500 U/mL) for 24 h and found that expression levels of ISGs *Stat1* and *Stat2* were significantly elevated by IFN-α ([Figure 3](#fig3){ref-type="fig"}A). By contrast, *Pparγ* expression levels in IFN-α-treated cells were reduced by 80% compared with those in control cells ([Figure 3](#fig3){ref-type="fig"}B). Exposure to IFN-α during adipocyte differentiation severely inhibited lipid accumulation and expression of adipogenic markers ([Figure 3](#fig3){ref-type="fig"}C and 3D). Taken together, these results indicate that induction of ISGs by LPS and IFN-α is accompanied by a reduction in *Pparγ* expression, leading to inhibition of adipogenesis.Figure 3IFN-α Inhibits Adipocyte Differentiation of Primary iWAT Preadipocytes(A) Induction of ISG expression in preadipocytes by IFN-α treatment (n = 3, three biological replicates).(B) Relative mRNA levels are reduced by IFN-α treatment in preadipocytes (n = 3, three biological replicates).(C) Oil red O staining of differentiated preadipocytes in the presence or absence of IFN-α.(D) Expression levels of adipogenic genes *Fabp4*, *Pparγ*, and *C/ebpα* in differentiated pre-adipocytes with or without IFN-α treatment (n = 3, three biological replicates).Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figures S6](#mmc1){ref-type="supplementary-material"}.

ATF7 Recruits G9a to Repress *Stat1* Expression in Preadipocytes {#sec2.4}
----------------------------------------------------------------

Given that ATF7 associates with histone dimethyltransferase G9a to suppress the expression of innate immune-related genes in macrophages ([@bib51]), we speculated that inhibition of ISG expression in adipocytes by ATF7 may occur in the same manner. To test this hypothesis, we first compared genes up-regulated by loss of ATF7 in macrophages and adipocytes. Among the top 250 genes up-regulated in *Atf7*^*−/−*^ macrophages, 58 also exhibited higher expression levels in *Atf7*^*−/−*^ adipocytes than in WT controls ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Pathway analysis of these 58 overlapping genes revealed their association with innate immune responses ([Figure S7](#mmc1){ref-type="supplementary-material"}B). To examine whether ATF7 inhibits the expression of ISGs via recruitment of G9a, we performed a co-immunoprecipitation (coIP) experiment in preadipocytes using anti-ATF7 antibody. The results demonstrated that ATF7 does indeed form a complex with endogenous G9a in preadipocytes ([Figure 4](#fig4){ref-type="fig"}A).Figure 4ATF7 Recruits G9a to Repress Stat1 Expression in Preadipocytes(A) Cell extracts of preadipocytes were immunoprecipitated with antibody (2F10)-recognizing ATF7 and immunoblotted with antibody against G9a.(B) Chromatin immunoprecipitation-qPCR analysis showing the binding of ATF7 to the *Stat1* gene promoter (n = 3, three biological replicates).(C) H3K9me2 enrichment on the *Stat1* promoter in WT and *Atf7*^*−/−*^ preadipocytes (n = 3, three biological replicates).(D) Relative *Stat1* mRNA levels in WT and *Atf7*^*−/−*^ preadipocytes (n = 3, three biological replicates).Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*\*p \< 0.01. See also [Figures S7](#mmc1){ref-type="supplementary-material"}.

STAT1 functions as a master regulator of the induction of ISGs by binding to ISREs. In macrophages, ATF7 directly binds the promoter region of *Stat1* to repress its expression ([@bib51]). Thus we speculated that *Stat1* may also be a target gene of ATF7 in preadipocytes. Chromatin immunoprecipitation-qPCR results confirmed that ATF7 binds directly to the promoter of the *Stat1* gene in preadipocytes ([Figure 4](#fig4){ref-type="fig"}B). Importantly, the loss of ATF7 led to lower H3K9me2 levels at the promoter region of the *Stat1* gene, and increased expression of *Stat1* in *Atf7*^*−/−*^ preadipocytes ([Figures 4](#fig4){ref-type="fig"}C and 4D). These findings imply that ATF7 may recruit G9a to the promoter region of *Stat1* and repress its expression through dimethylation of H3K9 in preadipocytes. Elevated STAT1 induced by loss of ATF7 in turn stimulates the expression of ISGs and inhibits adipogenesis.

Loss of ATF7 Promotes the Thermogenic Programming and Browning of iWAT {#sec2.5}
----------------------------------------------------------------------

The PPARγ agonist Rosi induces thermogenic gene programming of beige and brown adipocytes ([@bib34]). RNA-seq data showed that the majority of BAT-selective genes, including *Ucp1*, *Cidea*, *Pparα*, and *Otop1*, were evidently stimulated by Rosi treatment in both WT and *Atf7*^*−/−*^ cells ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, *Ucp1* exhibited higher expression in *Atf7*^*−/−*^ cells than in WT cells in the presence of Rosi ([Figure 5](#fig5){ref-type="fig"}B). Other thermogenic genes, such as *Cidea*, *Cox8b*, and *Pgc1α*, were also increased by the loss of ATF7, whereas *Prdm16* expression was not significantly different between WT and *Atf7*^*−/−*^ cells ([Figure 5](#fig5){ref-type="fig"}C). The acute stimulation of thermogenic genes in response to the activation of β-adrenergic receptors is one of the main functional characteristics of beige/brown adipocytes. To examine whether ATF7 is essential for this, differentiated WT and *Atf7*^*−/−*^ cells were treated with isoproterenol (Iso), a synthetic pan β-adrenergic receptor agonist. *Ucp1* expression levels were significantly increased in both WT and *Atf7*^*−/−*^ cells after Iso exposure for 4 h ([Figure 5](#fig5){ref-type="fig"}D). Of note, the increase in *Ucp1* expression stimulated by Iso was comparable in WT and *Atf7*^*−/−*^ cells (∼4-fold), implying that ATF7 may be dispensable for activation of beige cells via β-adrenergic receptors. These findings indicate that loss of ATF7 promotes thermogenic programming in a cell-autonomous manner.Figure 5Loss of ATF7 Promotes Thermogenic Gene Programming(A) Heatmap showing the expression levels of BAT-selective genes in WT and *Atf7*^*−/−*^ cells in the presence or absence of rosiglitazone (Rosi; n = 2, two biological replicates).(B) *Ucp1* gene expression levels in WT and *Atf7*^*−/−*^ differentiated primary iWAT preadipocytes in the presence or absence of Rosi (n = 3, three biological replicates). Data are presented as means ± SD. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak multiple comparison tests. \*\*p \< 0.01, \*\*\*p \< 0.001.(C) Thermogenic gene expression levels in differentiated WT and *Atf7*^*−/−*^ primary iWAT preadipocytes treated with Rosi (n = 3, three biological replicates). Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*p \< 0.05.(D) Relative mRNA levels of *Ucp1* in differentiated WT and *Atf7*^*−/−*^ primary iWAT preadipocytes before and after treatment with 2 μM isoproterenol (Iso) for 4 h (n = 3, three biological replicates). Data are presented as means ± SD. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak multiple comparison tests. \*p \< 0.05, \*\*\*p \< 0.001 versus WT (no Iso treatment).

To determine whether ATF7 contributes to thermogenic programming of beige or brown adipocyte *in vivo*, we examined UCP1 protein levels in BAT and iWAT in WT and *Atf7*^*−/−*^ mice. We found that loss of ATF7 did not affect UCP1 abundance in BAT, but UCP1 expression was increased in iWAT in *Atf7*^*−/−*^ mice compared with WT controls ([Figure 6](#fig6){ref-type="fig"}A). To assess the morphology of adipocytes in iWAT, we performed hematoxylin and eosin staining of iWAT sections, and more multilocular adipocytes were observed in iWAT from *Atf7*^*−/−*^ mice than from WT controls ([Figure 6](#fig6){ref-type="fig"}B). Importantly, immunohistochemical staining showed that the number of UCP1-positive cells was markedly increased by ablation of ATF7, consistent with evaluated UCP1 protein levels in iWAT from ATF7 KO cells ([Figures 6](#fig6){ref-type="fig"}A and 6B). To explore gene expression profiles in iWAT induced by the loss of ATF7, we performed microarray analysis using RNA isolated from iWAT in *Atf7*^*−/−*^ and WT control cells. The results revealed that 115 genes, including *Ucp1*, *Cidea*, *Pgc1α*, and *Pparα*, were up-regulated in *Atf7*^*−/−*^ iWAT compared with control tissue ([Figure 6](#fig6){ref-type="fig"}C). Pathway analysis revealed that these genes are associated with adaptive thermogenesis and fatty acid metabolism ([Figure 6](#fig6){ref-type="fig"}D). Subsequent qPCR results further confirmed that several brown-fat-selective genes including *Ucp1*, *Cidea*, *Pparα*, and *Ntrk3*, and mitochondrial genes including *Cox7a1* and *Cox8b*, were increased in iWAT following loss of ATF7, whereas there was no change in the expression of common adipocyte genes including *C/ebpα*, *Fabp4*, and *Pparγ* ([Figure 6](#fig6){ref-type="fig"}E). However, except for *Ntrk3*, expression of brown-fat-selective genes did not differ between WT and *Atf7*^*−/−*^ BAT. In addition, there were no changes in the expression of mitochondrial and common adipocyte genes in *Atf7*^*−/−*^ BAT compared with WT controls ([Figure S8](#mmc1){ref-type="supplementary-material"}A). In line with the results of thermogenic gene expression in BAT, there is no significant difference in the tolerance to acute cold exposure between *Atf7*^*−/−*^ and WT littermates ([Figure S8](#mmc1){ref-type="supplementary-material"}B). Taken together, the *in vivo* and *in vitro* results suggest that ATF7 contributes to the regulation of beige adipocyte biogenesis by suppressing thermogenic gene programming.Figure 6ATF7 Ablation Promotes Browning of iWAT(A) Relative UCP1 protein levels in BAT and iWAT of WT and *Atf7*^*−/−*^ littermates (n = 2, two biological replicates).(B) Hematoxylin and eosin staining (upper) and UCP1 immunohistochemical analysis (lower) of iWAT from WT and *Atf7*^*−/−*^ littermates.(C) Heatmap depicting expression levels of differentially expressed genes induced by loss of ATF7 in WT and *Atf7*^*−/−*^ littermates (n = 3, three biological replicates).(D) Pathway analysis for up-regulated genes in *Atf7*^*−/−*^ iWAT.(E) Expression of brown-fat-selective genes, common adipocyte genes, and mitochondrial genes in iWAT from WT and *Atf7*^*−/−*^ littermates (n = 3, three biological replicates).Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*p \< 0.05. See also [Figures S8](#mmc1){ref-type="supplementary-material"}.

Overexpression of ATF7 Inhibits Thermogenic Gene Programming {#sec2.6}
------------------------------------------------------------

To further explore the molecular mechanism of ATF7 functions in beige cell biogenesis, we used C3H10T1/2 multipotent mesenchymal cells, which have the capacity to undergo brown or beige adipogenic differentiation when treated with an adipogenic cocktail. The results revealed no obvious change in ATF7 protein abundance during differentiation, but phosphorylation of ATF7 was induced during the later stages of differentiation ([Figure 7](#fig7){ref-type="fig"}A). To examine the role of ATF7 in differentiation, FLAG-tagged ATF7 was expressed in C3H10T1/2 cells via a lentiviral vector, and overexpression of ATF7 did not affect lipid accumulation, as shown by oil red O staining ([Figure 7](#fig7){ref-type="fig"}B). However, RNA-seq data indicated that expression of brown-fat-selective genes, including *Ucp1*, *Cidea*, *Pparα*, *Kcnk3*, and *Otop1*, was reduced following overexpression of ATF7 ([Figure 7](#fig7){ref-type="fig"}C). Notably, these down-regulated genes induced by ATF7 overexpression are related to fatty acid and lipid metabolism ([Figure 7](#fig7){ref-type="fig"}D), similar to the pathways associated with genes up-regulated in *Atf7*^*−/−*^ iWAT ([Figure 6](#fig6){ref-type="fig"}D). We next compared genes down-regulated by ATF7 overexpression in differentiated C3H10T1/2 cells and up-regulated by ATF7 ablation in iWAT. As shown in the Venn diagram ([Figures 7](#fig7){ref-type="fig"}E), 22 genes including *Ucp1*, *Cidea*, *Pparα*, and *Cox7a1* overlap between these two gene sets. The results of qPCR experiments further confirmed that ATF7 overexpression led to a reduction in the expression of brown-fat-selective genes *Cidea*, *Elovl3*, and *Pparα*, and mitochondrial genes *Cox7a1* and *Cox8b* ([Figure 7](#fig7){ref-type="fig"}F). Although overexpression of ATF7 strongly inhibited *Ucp1* expression, there was a 3-fold increase in *Ucp1* expression after Iso treatment in ATF7-overexpressing cells, whereas Iso stimulation led to a 3-fold increase in *Ucp1* expression in control cells ([Figure 7](#fig7){ref-type="fig"}G). These results further suggest that ATF7 does not participate in the acute activation of *Ucp1* via β-adrenergic stimulation.Figure 7Overexpression of ATF7 Represses Thermogenic Gene Programming(A) ATF7 protein and phosphorylation levels during C3H10T1/2 cell differentiation measured by immunoblotting using antibodies against ATF7 (1A7) and Phospho-ATF7 (Thr53), respectively.(B) Oil red O staining of control and ATF7-overexpressing cells 7 days after induction of differentiation.(C) Heatmap depicting expression levels of differentially expressed genes in ATF7-overexpressing C3H10T1/2 cells compared with control cells (n = 2, two biological replicates).(D) Pathway analysis for down-regulated genes induced by ATF7 overexpression.(E) Venn diagram showing the number of overlapping up-regulated genes in *Atf7*^*−/−*^ iWAT and down-regulated genes in ATF7-overexpressing cells.(F) Relative mRNA levels of thermogenic genes in differentiated control and ATF7-overexpressing cells (n = 3, three biological replicates). Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*\*p \< 0.01, \*\*\*p \< 0.001.(G) *Ucp1* gene expression levels before and after treatment with 2 μM isoproterenol (Iso) for 4 h in control and ATF7-overexpressing cells (n = 3, three biological replicates). Data are presented as means ± SD. Statistical analysis was performed using two-way ANOVA followed by Holm-Sidak multiple comparison tests. \*p \<0.05, \*\*p \< 0.01 versus controls (without Iso treatment), \*\*\*p \< 0.001 versus controls (with Iso treatment).

ATF7 Associates with C/EBPβ and Regulates Histone Modification of *Ucp1* Enhancers {#sec2.7}
----------------------------------------------------------------------------------

To explore the molecular mechanism underlying the repressive role of ATF7 in thermogenic gene programming, we examined whether ATF7 associates with PRDM16, which is the master regulator of the thermogenic gene programming. However, coIP experiment was performed using 293T cells, and the results indicated that ATF7 interacts with C/EBPβ, but not with PRDM16 ([Figure 8](#fig8){ref-type="fig"}A), implying that ATF7-induced suppression of thermogenic gene programming is likely not mediated by PRDM16. To further confirm whether ATF7 associated with C/EBPβ in the adipocytes, coIP experiment was performed using ATF7-overexpressing C3H10T1/2 cells after differentiation in the presence of Rosi for 4 days. We found that the interaction between ATF7 and endogenous C/EBPβ could be detected in the adipocytes ([Figure 8](#fig8){ref-type="fig"}B). Recent study demonstrated that C/EBPβ binds to the enhancer regions of thermogenic genes and controls their expression in response to IL-10 treatment ([@bib23], [@bib36]). Although overexpression of ATF7 did not affect the binding of C/EBPβ to Ucp1 enhancers located 12, 5, and 2.5 kb upstream of transcription start sites, the elevated H3K9me2 levels on these regions were detected in the ATF7-overexpressing C3H10T1/2 cells after differentiation for 5 days ([Figure 8](#fig8){ref-type="fig"}C). As these enhancer regions contain the CRE (cAMP response element) sequence, we speculated that ATF7 may bind to these regions ([@bib36]). The results of quantitative chromatin immunoprecipitation (qChIP) analysis confirmed that ATF7 directly binds to these enhancers in C3H10T1/2 cells after differentiation for 5 days ([Figure 8](#fig8){ref-type="fig"}D). We also investigated the effect of ATF7 deficiency on H3K9me2 levels on those enhancers, and levels on the enhancer located 5 kb upstream from the transcription start site in *Atf7*^*−/−*^ primary iWAT preadipocytes were lower than in WT cells after differentiation in the presence of Rosi for 7 days ([Figure 8](#fig8){ref-type="fig"}E), indicating that ATF7 silences *Ucp1* gene expression by increasing H3K9me2 levels. Thus these findings demonstrate that ATF7 associates with C/EBPβ, binds enhancers of the *Ucp1* gene, and represses gene expression via H3K9me2.Figure 8ATF7 Interacts with C/EBPβ and Regulates H3K9me2 Levels of *Ucp1* Enhancers(A) 293T cells transfected with C/EBPβ-His, HA-Prdm16, and FLAG-ATF7. Lysates were immunoprecipitated with anti-hemagglutinin (HA) antibody and immunoblotted with antibodies against Prdm16, ATF7, and C/EBPβ, respectively.(B) Co-immunoprecipitation of FLAG-ATF7 and C/EBPβ in ATF7-overexpressing C3H10T1/2 cells after differentiation in the presence of Rosi for 4 days.(C) Chromatin immunoprecipitation (ChIP)-PCR analyses showing binding of C/EBPβ and enrichment of H3K9me2 on *Ucp1* enhancers in control and ATF7-overexpressing C3H10T1/2 cells after differentiation in the presence of Rosi for 5 days (n = 3, three biological replicates).(D) ChIP-PCR analyses showing binding of ATF7 to *Ucp1* enhancers in differentiated C3H10T1/2 cells after differentiation in the presence of Rosi for 5 days (n = 3, three biological replicates).(E) H3K9me2 enrichment on enhancers of *Ucp1* genes in WT and *Atf7*^*−/−*^ primary iWAT preadipocytes after differentiation in the presence of Rosi for 7 days (n = 3, three biological replicates).Data are presented as means ± SD. Statistical analysis was performed using two-tailed unpaired Student\'s t tests. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

Discussion {#sec3}
==========

In this study, we found that loss of ATF7 impairs adipogenesis and induces expression of innate immune-related genes. A previous study demonstrated that ATF7 represses innate immune gene expression in macrophages via modulation of H3K9 dimethylation levels at promoter regions ([@bib51]). Consistent with this function in macrophages, our results demonstrated that ATF7 also functions as a repressive regulator of innate immune genes in preadipocytes. Interestingly, preadipocytes can act as macrophage-like immune cells and express the same cytokines as macrophages ([@bib7]). Under certain conditions, preadipocytes can be converted to macrophages, further implying that they may share the same regulatory mechanisms regarding regulation of innate immune responses ([@bib6]). We therefore predicted that the inhibitory function of ATF7 in innate immune-related gene expression in preadipocytes is mediated by association with G9a. In line with our hypothesis, deletion of G9a led to the activation of innate immune genes in brown preadipocytes, although G9a blocked adipogenesis by suppressing *Pparγ* expression ([@bib49]).

Our results demonstrated that the promoter regions of up-regulated genes contain ISRE motifs that are recognized by STAT1. ATF7 directly binds to the promoter of *Stat1* and represses its transcription in preadipocytes via epigenetic regulation, implying that the inhibitory effect of ATF7 on innate immune gene expression is mainly mediated by STAT1. Of note, the JAK/STAT1 signaling pathway reportedly mediates the inhibitory effect of IFN-α on adipocyte differentiation ([@bib24]). Moreover, *in vitro* studies suggest that STAT1 binds to the *Pparγ2* promoter in 3T3-L1 adipocytes and represses its transcription ([@bib15]). Thus ATF7 may facilitate adipogenesis by indirectly regulating *Pparγ* expression via STAT1. Consistent with this possibility, we observed that the *Pparγ* agonist rosiglitazone could rescue impaired adipogenesis in ATF7-deficient primary cells. It was previously demonstrated that LPS treatment results in the defective adipogenic potential of preadipocytes independently of nuclear factor-κB ([@bib52]), and phosphorylation of ATF7 in response to LPS treatment contributes to the activation of innate immune genes ([@bib51]). Our results showed that overexpression of ATF7 blocks LPS-induced activation of innate immune genes, further suggesting that ATF7 mediates the inhibitory effect of LPS on adipogenesis.

Adipocyte differentiation and thermogenic gene programming are controlled by distinct transcriptional regulatory mechanisms, even though several common transcriptional regulators, such as TLE3 and ZFP423, are shared by these two processes. Both TLE3 and ZFP423 stimulate adipogenesis through activation of PPARγ ([@bib48], [@bib11]); TLE3 suppresses thermogenic gene programming by disrupting interactions between PRDM16 and PPARγ ([@bib47]), whereas ZFP423 inhibits thermogenic gene programming by suppressing Ebf2 ([@bib42]). However, ATF2 acts as a positive regulator during adipogenesis and stimulates thermogenic genes ([@bib27], [@bib4]). Our results reveal that, similar to TLE3 and ZFP423, ATF7 promotes adipogenesis while inhibiting adipocyte thermogenic gene programming. Interestingly, unlike ATF2, ATF7 was found to be dispensable for acute induction of *Ucp1* by activation of β-adrenergic receptors. Although the browning of iWAT was observed in *Atf7*^*−/−*^ mice, a difference in thermogenic gene expression in BAT was not detected. These findings suggest that ATF7 mainly contributes to the regulation of beige cell biogenesis, rather than the stimuli-induced acute enhancement of *Ucp1* expression.

Beige adipocyte biogenesis is regulated by a number of epigenetic regulators ([@bib17]), and accumulating evidence suggests that the dynamic enhancer epigenome is tightly correlated with thermogenic gene programming in adipocytes ([@bib37], [@bib25]). Notably, the amount of the repressive chromatin marker H3K9me2 on enhancers of thermogenic genes, including *Ucp1* and *Cidea*, is reduced, whereas levels of the active histone marker H3K27ac are increased during brown or beige cell biogenesis ([@bib23], [@bib3]). Deletion of HDAC3 in adipose tissue leads to increased H3K27 acetylation of *Ucp1* and *Pparα* enhancers, resulting in the browning of WAT ([@bib9]). Our results showed that ATF7 associates with C/EBPβ and represses thermogenic gene programming via H3K9 dimethylation on enhancers of *Ucp1*. A recent study demonstrated that the recruitment of C/EBPβ and ATF2 is accompanied by altered histone modification on enhancer regions, which mediates the inhibitory effect of IL-10 signaling on thermogenic gene programming ([@bib36]). C/EBPβ is essential for brown and beige adipocyte development through formation of a transcriptional complex with PRDM16 ([@bib19]).

We identified that ATF7 as the transcriptional repressor of IFN signaling in adipocytes. Recent study shows that the activation of ISGs induced by IFN-α impairs the thermogenic gene programming and disrupts the mitochondrial structure in the brown adipocytes ([@bib21]). Importantly, repression of the IFN signaling by blocking of JAK-STAT pathway promotes the browning of human adipocytes ([@bib32]), highlighting the repressive role of IFN-JAK-STAT signaling in thermogenic gene expression. However, we found that loss of ATF7 promotes thermogenic gene programming, although ISGs exhibited higher level in *Atf7*^*−/−*^ adipocytes, suggesting that ATF7 controls the expression of thermogenic genes mainly through repressive epigenetic modification on the enhancers rather than the repression of JAK-STAT pathway in adipocytes. Enhancement of beige adipocyte biogenesis by a loss of ATF7 by regulating the dimethylation of H3K9 on thermogenic gene enhancers might be more dominant compared with suppression of the same by the JAK-STAT pathway.

Expression of thermogenic genes is closely linked to environmental factors such as low temperature. Repeated cold exposure leads to increased activity in brown and beige cells, which confers beneficial effects to metabolic homeostasis ([@bib1]). A recent study indicates that paternal cold exposure before conception can enhance thermogenic gene expression in offspring by reprogramming the sperm epigenome ([@bib45]). Notably, dATF2, the homolog of mammalian ATF7 in *Drosophila*, acts as a transcriptional repressor and mediates stress-induced epigenetic inheritance ([@bib40]). Combined with our current results, these findings suggest that ATF7 may mediate epigenetic changes in sperm induced by cold exposure and contribute to enhanced brown or beige cell activity in the offspring of a father that experienced cold before conception.

Limitations of Study {#sec3.1}
--------------------

Our results demonstrate that ATF7 can associate with C/EBPβ in adipocytes, although ATF7 may not disrupt the interaction between Prdm16 and C/EBPβ. However, at present, we cannot rule out the possibility that ATF7 blocks the association of C/EBPβ with other partners, such as the SWI/SNF complex ([@bib22]), resulting in a reduction in C/EBPβ transcriptional activity. Furthermore, whether binding of ATF7 to enhancers of Ucp1 is dependent on C/EBPβ also needs further investigation.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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